Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neos Therapeutics, Inc.NEOS · Entity 141061 | Chief Executive Officer | March 01, 2018 | March 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neos Therapeutics, Inc.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,748 |
Reported balance
After 2018-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 25,000 · Balance 160,748 F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2028-03-01 | Direct | 75,000 |
Reported balance
After 2018-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-01 · Grant · Acquired 75,000 · Balance 75,000 F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019.
F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altimmune, Inc.
Report date January 30, 2026 · Filed February 02, 2026
Section 16 reporting ended · disclosed 2026-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 424,519 |
Ending reported balance
After 2026-01-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-30 · Exercise / conversion · Acquired 26,775 · Balance 429,225 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-01-30 · Tax withholding · Disposed 11,632 · Balance 417,593 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Row 3 · 2026-01-31 · Grant · Acquired 6,926 · Balance 424,519 F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026 F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,775 |
Reported balance
After 2026-01-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-30 · Exercise / conversion · Disposed 26,775 · Balance 26,775 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025
F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2018 Filed Dec 4, 2018 21:08 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 211,486 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001012975-18-001273 · edgar.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,486 Underlying: Common Stock, par value $0.0001 · 211,486 shares Expires 2028-11-30 F3 · derivative.exercise_date: One-fourth of the shares underlying the stock option will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the stock option will vest monthly, such that the shares underlying the stock option will be fully vested on the fourth anniversary of the grant date, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:08 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 322,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-18-001273 · edgar.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,907 F1 · shares: One-fourth of the restricted shares will vest on the one-year anniversary of the grant date and thereafter 1/48th of the restricted shares will vest monthly, such that the restricted shares will be fully vested on the fourth anniversary of the grant date, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date. F2 · price: Represents a grant of restricted stock pursuant to the Company's 2018 Inducement Grant Plan. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:15 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001104659-18-014878 · a4.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-03-01 F2 · derivative.exercise_date: This stock option will vest in four equal, annual installments beginning on March 1, 2019. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:15 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-014878 · a4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,748 F1 · security: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 16:15 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Tax withholdingCommon Stock | 14,895 | $8.00 | $119,160.00 |
DisclosureSEC source: 0001104659-17-062531 · a4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,748 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| May 01, 2017 Filed May 2, 2017 21:09 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-17-029071 · a4.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-05-01 F2 · derivative.exercise_date: This stock option will vest in four equal, annual installments beginning on May 1, 2018. Read SEC document |
| May 01, 2017 Filed May 2, 2017 21:09 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-029071 · a4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,643 F1 · security: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on May 1, 2018. Read SEC document |
| October 17, 2016 Filed Oct 18, 2016 16:23 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Tax withholdingCommon Stock | 9,709 | $6.37 | $61,846.33 |
DisclosureSEC source: 0001179110-16-030768 · edgar.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,643 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:01 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001104659-16-148695 · a4.xml · derivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 62,500 shares Expires 2026-04-01 F1 · derivative.exercise_date: On April 1, 2016, the reporting person was granted performance based options to purchase 75,000 shares of stock. The option vests in four equal, annual installments beginning on April 1, 2017, provided that certain performance based metrics have been met or satisfied on or before September 30, 2016, of which the performance criteria were met with respect to 62,500 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.